William Blair Issues Positive Forecast for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at William Blair boosted their FY2025 EPS estimates for shares of Exelixis in a research report issued on Sunday, January 12th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $1.69 per share for the year, up from their previous forecast of $1.44. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share.

Several other brokerages also recently weighed in on EXEL. Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and raised their price target for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. Wells Fargo & Company increased their price objective on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. Stifel Nicolaus upped their price target on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. Finally, Truist Financial lifted their price objective on shares of Exelixis from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.75.

Exelixis Stock Up 4.5 %

NASDAQ EXEL opened at $37.27 on Wednesday. Exelixis has a 52 week low of $20.01 and a 52 week high of $37.31. The company has a 50 day moving average price of $34.92 and a 200 day moving average price of $29.08. The firm has a market cap of $10.64 billion, a PE ratio of 23.89, a price-to-earnings-growth ratio of 0.88 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period last year, the business posted $0.10 EPS. The business’s revenue was up 14.3% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. grew its position in shares of Exelixis by 15.2% in the second quarter. Victory Capital Management Inc. now owns 116,806 shares of the biotechnology company’s stock valued at $2,625,000 after purchasing an additional 15,368 shares during the period. Federated Hermes Inc. lifted its position in shares of Exelixis by 1.0% in the second quarter. Federated Hermes Inc. now owns 227,909 shares of the biotechnology company’s stock valued at $5,121,000 after acquiring an additional 2,333 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Exelixis by 3.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 465,048 shares of the biotechnology company’s stock worth $10,450,000 after acquiring an additional 14,443 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Exelixis by 7.3% during the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after purchasing an additional 349,837 shares in the last quarter. Finally, Edgestream Partners L.P. lifted its holdings in Exelixis by 128.6% in the 2nd quarter. Edgestream Partners L.P. now owns 114,785 shares of the biotechnology company’s stock valued at $2,579,000 after purchasing an additional 64,571 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 314,736 shares of company stock valued at $10,849,110 over the last ninety days. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.